GAITHERSBURG, Md., Sept. 02, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the Company will participate in the FBR 2nd Annual Healthcare Conference and the Citi 10th Annual Biotech Conference.
Conference details are as follows:
FBR 2nd Annual Healthcare Conference
Date: Wednesday, September 9, 2015
Forum: One-on-one meetings
Location: Four Seasons Hotel, Boston
Citi 10th Annual Biotech Conference
Date: Thursday, September 10, 2015
Forum: Panel discussion, Preventing and Treating Viral Infections: Vaccines and Antivirals
Time: 8:00 – 8:55 a.m. US Eastern Time
Location: Mandarin Oriental Hotel, New York
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the company’s website, novavax.com.
Contact: Novavax, Inc. Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Andrea N. Flynn, Ph.D. Senior Manager, Investor Relations email@example.com 240-268-2000 Russo Partners, LLC David Schull Todd Davenport, Ph.D. firstname.lastname@example.org email@example.com 212-845-4271